Susan Fox
Susan Fox
Associate Professor University of Toronto
Verified email at uhnresearch.ca
Title
Cited by
Cited by
Year
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): scale presentation and clinimetric testing results
CG Goetz, BC Tilley, SR Shaftman, GT Stebbins, S Fahn, ...
Movement disorders: official journal of the Movement Disorder Society 23 (15 …, 2008
31102008
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease
K Seppi, D Weintraub, M Coelho, S Perez‐Lloret, SH Fox, ...
Movement Disorders 26 (S3), S42-S80, 2011
8532011
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
SH Fox, R Katzenschlager, SY Lim, B Ravina, K Seppi, M Coelho, ...
Movement Disorders 26 (S3), S2-S41, 2011
6002011
Prevalence of repetitive and reward-seeking behaviors in Parkinson disease
V Voon, K Hassan, M Zurowski, M De Souza, T Thomsen, S Fox, AE Lang, ...
Neurology 67 (7), 1254-1257, 2006
4642006
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease
C Zadikoff, SH Fox, DF Tang‐Wai, T Thomsen, RMA De Bie, P Wadia, ...
Movement disorders 23 (2), 297-299, 2008
4112008
Medication-related impulse control and repetitive behaviors in Parkinson disease
V Voon, SH Fox
Archives of Neurology 64 (8), 1089-1096, 2007
4012007
Factors associated with dopaminergic drug–related pathological gambling in Parkinson disease
V Voon, T Thomsen, JM Miyasaki, M de Souza, A Shafro, SH Fox, ...
Archives of Neurology 64 (2), 212-216, 2007
3662007
Prospective prevalence of pathologic gambling and medication association in Parkinson disease
V Voon, K Hassan, M Zurowski, S Duff-Canning, M De Souza, S Fox, ...
Neurology 66 (11), 1750-1752, 2006
3642006
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study
KA Sieradzan, SH Fox, M Hill, JPR Dick, AR Crossman, JM Brotchie
Neurology 57 (11), 2108-2111, 2001
3202001
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
MF Bastide, WG Meissner, B Picconi, S Fasano, PO Fernagut, M Feyder, ...
Progress in neurobiology 132, 96-168, 2015
2782015
The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease
P Huot, TH Johnston, JB Koprich, SH Fox, JM Brotchie
Pharmacological reviews 65 (1), 171-222, 2013
2472013
International Parkinson and movement disorder society evidence‐based medicine review: update on treatments for the motor symptoms of Parkinson's disease
SH Fox, R Katzenschlager, SY Lim, B Barton, RMA de Bie, K Seppi, ...
Movement Disorders 33 (8), 1248-1266, 2018
2142018
Serotonin 2A receptors and visual hallucinations in Parkinson disease
B Ballanger, AP Strafella, T van Eimeren, M Zurowski, PM Rusjan, ...
Archives of neurology 67 (4), 416-421, 2010
2072010
Overview of the extranigral aspects of Parkinson disease
SY Lim, SH Fox, AE Lang
Archives of neurology 66 (2), 167-172, 2009
1992009
Clinical spectrum of levodopa‐induced complications
CC Aquino, SH Fox
Movement Disorders 30 (1), 80-89, 2015
1922015
A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease
M van der Stelt, SH Fox, M Hill, AR Crossman, S Petrosino, V Di Marzo, ...
The FASEB journal 19 (9), 1140-1142, 2005
1862005
Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
SH Fox, B Henry, M Hill, A Crossman, J Brotchie
Movement disorders: official journal of the Movement Disorder Society 17 (6 …, 2002
1722002
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson’s disease
B Henry, S Duty, SH Fox, AR Crossman, JM Brotchie
Experimental neurology 183 (2), 458-468, 2003
1702003
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's …
AJ Moskowitz, H Schöder, J Yahalom, SJ McCall, SY Fox, J Gerecitano, ...
The Lancet Oncology 16 (3), 284-292, 2015
1682015
Fipamezole (JP‐1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson …
JM Savola, M Hill, M Engstrom, H Merivuori, S Wurster, SG McGuire, ...
Movement disorders: official journal of the Movement Disorder Society 18 (8 …, 2003
1672003
The system can't perform the operation now. Try again later.
Articles 1–20